These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11061029)

  • 1. A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. Urosepsis Study Group.
    Luchi M; Morrison DC; Opal S; Yoneda K; Slotman G; Chambers H; Wiesenfeld H; Lemke J; Ryan JL; Horn D
    J Endotoxin Res; 2000; 6(1):25-31. PubMed ID: 11061029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic-induced endotoxin release in patients with gram-negative urosepsis: a double-blind study comparing imipenem and ceftazidime.
    Prins JM; van Agtmael MA; Kuijper EJ; van Deventer SJ; Speelman P
    J Infect Dis; 1995 Sep; 172(3):886-91. PubMed ID: 7658090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections.
    Byl B; Clevenbergh P; Kentos A; Jacobs F; Marchant A; Vincent JL; Thys JP
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):804-7. PubMed ID: 11783697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential antibiotic-induced endotoxin release in severe melioidosis.
    Simpson AJ; Opal SM; Angus BJ; Prins JM; Palardy JE; Parejo NA; Chaowagul W; White NJ
    J Infect Dis; 2000 Mar; 181(3):1014-9. PubMed ID: 10720525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic induced endotoxin release and clinical sepsis: a review.
    Holzheimer RG
    J Chemother; 2001 Nov; 13 Spec No 1(1):159-72. PubMed ID: 11936361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of endotoxin release and cytokine production induced by antibiotics in patients with Gram-negative nosocomial pneumonia.
    Maskin B; Fontán PA; Spinedi EG; Gammella D; Badolati A
    Crit Care Med; 2002 Feb; 30(2):349-54. PubMed ID: 11889308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
    Buijs J; Dofferhoff AS; Mouton JW; van der Meer JW
    J Antimicrob Chemother; 2007 May; 59(5):926-33. PubMed ID: 17395686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria.
    Gogos CA; Skoutelis A; Lekkou A; Drosou E; Starakis I; Marangos MN; Bassaris HP
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2793-8. PubMed ID: 15273083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release.
    Vianna RC; Gomes RN; Bozza FA; Amâncio RT; Bozza PT; David CM; Castro-Faria-Neto HC
    Shock; 2004 Feb; 21(2):115-20. PubMed ID: 14752283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study.
    Dofferhoff AS; Nijland JH; de Vries-Hospers HG; Mulder PO; Weits J; Bom VJ
    Scand J Infect Dis; 1991; 23(6):745-54. PubMed ID: 1815338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis.
    Morrison DC; Bucklin SE
    Scand J Infect Dis Suppl; 1996; 101():3-8. PubMed ID: 9060044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical presentations, risk factors and outcomes of ceftazidime-resistant Gram-negative endophthalmitis.
    Dave VP; Pathengay A; Nishant K; Pappuru RR; Sharma S; Sharma P; Narayanan R; Jalali S; Mathai A; Das T
    Clin Exp Ophthalmol; 2017 Apr; 45(3):254-260. PubMed ID: 27616274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
    Norrby SR; Finch RG; Glauser M
    J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
    J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in gram-negative sepsis.
    Horn DL; Opal SM; Lomastro E
    Scand J Infect Dis Suppl; 1996; 101():9-13. PubMed ID: 9060045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections.
    Kongnakorn T; Wagenlehner F; Falcone M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Int J Antimicrob Agents; 2019 Nov; 54(5):633-641. PubMed ID: 31202921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes.
    Dofferhoff AS; Esselink MT; de Vries-Hospers HG; van Zanten A; Bom VJ; Weits J; Vellenga E
    J Antimicrob Chemother; 1993 Mar; 31(3):373-84. PubMed ID: 8486571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of gram-negative sepsis.
    Bucklin SE; Morrison DC
    J Infect Dis; 1995 Dec; 172(6):1519-27. PubMed ID: 7594711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.